Rate My Professor Gregory Fox

Fox's primary research interests lie in the detection, treatment, and prevention of tuberculosis, particularly drug-resistant forms, in resource-limited settings. He leads prominent clinical trials, including the FLIRT Trial on treatment regimens for isoniazid-resistant tuberculosis and the VQUIN trial evaluating levofloxacin for preventing multidrug-resistant tuberculosis among household contacts. With over 99 publications cited more than 8,800 times on Google Scholar, key works encompass systematic reviews and meta-analyses on tuberculosis contact investigation, studies on host-protein biomarkers distinguishing asymptomatic tuberculosis, and evaluations of long-term outcomes for multidrug-resistant tuberculosis patients. His efforts have attracted substantial funding, such as NHMRC Investigator Grants, a $3 million award for a new tuberculosis research centre, and multimillion-dollar DFAT grants. Major honors include the 2021 NHMRC David Cooper Clinical Trials and Cohort Studies Award as the highest-ranked recipient, the 2015 Young Innovator in TB Research Award from the International Union Against Tuberculosis and Lung Disease, and the 2022 Ho Chi Minh Scientific Prize for advancements in respiratory health. Fox teaches courses on drug-resistant tuberculosis, clinical trial design and implementation, meta-analysis, and clinical epidemiology, shaping future experts in respiratory medicine and public health.